February 2019
Corporate HQ
Newcastle, UK

Sterling Pharma Solutions is a specialist provider of Active Pharmaceutical Ingredient (‘API’) development and manufacturing services to the innovator segment of the global biopharmaceutical industry.

Sterling delivers a full-service offering throughout the entire product lifecycle, from clinical development to commercial supply. Sterling specialises in complex and difficult to manufacture APIs, with a reputation for world-class quality standards and capabilities.

Enablement & Alignment

Shared vision to create a global Top 10 western based small molecule CDMO focused on innovator pharma with development of early phase Drug Substance and Drug Product offering.

A culture based on transparent and relatable values and service offering centred on science.

Maintain being a destination employer that cares for employees and ESG.

Capability & Capacity

Significant investment to build out team from a single site governance infrastructure to that suitable for a global platform.

Investment in platform capabilities (IT, BD team, Data analytics, Paperless, and Pharma 4.0).

Investment in additional platform capabilities (Solid State, Milling and Micronisation).

Building Strategic Footprints

Entry into US to establish direct presence in world’s largest pharma innovator market.

Organic build or inorganic acquisition of HPAPI capability.

Acquisition of feeder sites and small scaled manufacturing capacity that is complimentary to UK facility to provide capacity headroom and ability to efficiently service scale requirements of innovator molecules through their lifecycle.

Acquisition of small scale to benefit from multiple arbitrage at exit.